United States (Change Country)Tivozanib (AV-951) Chemical Structure
Tivozanib (AV-951) is an orally bioavailable potent VEGFR-1, 2 and 3, cKit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively. Tivozanib (AV-951) has potential antiangiogenic and antineoplastic activities. Tivozanib (AV-951) inhibits c-Kit and PDGFR at 10-times higher concentrations. Tivozanib (AV-951) is a novel oral quinoline urea derivative. Preclinical data indicate that AV-951 blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo. Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients. Tivozanib (AV-951) is under early clinical investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients. [1]
[1] Drugs Fut 2009;34(10): 793
| Molecular Weight (WM): | 454.86 |
|---|---|
| Formula: | C22H19ClN4O5 |
| Solubility(R.T.:25°C): | DMSO 20mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL |
A collection of 715 inhibitors
A collection of 271 kinase inhibitors
A collection of 785 FDA approved drugs
A collection of 144 natural products
A collection of 84 chemotherapeutic agents
A collection of 1463 bioactive compounds
A collection of 117 tyrosine kinase inhibitors
Keywords:buy Tivozanib (AV-951) | Tivozanib (AV-951) supplier | purchase Tivozanib (AV-951) | Tivozanib (AV-951) cost | Tivozanib (AV-951) manufacturer | order Tivozanib (AV-951) | Tivozanib (AV-951) distributor